Biohaven .(US:BHVN) Prnewswireยท2025-08-14 12:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Biohaven Ltd. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its product candidates and their regulatory prospects [1][2]. Group 1: Allegations - The complaint claims that during the class period from March 24, 2023, to May 14, 2025, Biohaven overstated the regulatory prospects of its product candidate, troriluzole, as a treatment for SCA [1]. - It is alleged that the efficacy and clinical prospects of BHV-7000 for bipolar disorder were also overstated [1]. - The revelations of these overstated claims are likely to have a significant negative impact on Biohaven's business and financial condition [1]. Group 2: Class Action Details - Shareholders who purchased shares of BHVN during the specified class period are encouraged to register for the class action, with a deadline of September 12, 2025, to seek lead plaintiff status [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].